Is it true that ribociclib/ribociclib is very effective? Is it reliable?

Ribociclib is a CDK4/6 inhibitor widely used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced or metastatic breast cancer. Regarding the question "Is it true that Riboxiclib is very effective? Is it reliable?", the answer can be clearly affirmed from the results of many large-scale international clinical studies. Riboxiclib inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), causing cancer cells to stall in the G1 phase and prevent them from continuing to proliferate, thereby effectively controlling tumors.

According to multiple clinical trials, Riboxiclib combined with aromatase inhibitors or fulvestrant has significantly prolonged the progression-free survival (PFS) and overall survival (OS) of patients. For example, in the MONALEESA-7 study, for premenopausal breast cancer patients, the median overall survival in the combination treatment group reached 58.7 months, while the median overall survival in the control group was only 48 months. This data has been reported many times and recommended by international cancer guidelines such as ESMO and NCCN as a first-line treatment option for HR+/HER2– breast cancer.

Riboxiclib“Reliability” is not only reflected in its prolonged survival, but also its relatively good safety and patient acceptability. Compared with other CDK4/6 inhibitors, ribociclib has predictable and manageable adverse effects under dose control. The most common adverse reactions are reversible neutropenia, mild liver function abnormalities, and QT interval prolongation, but clinicians can usually achieve risk control by regularly monitoring blood routine and electrocardiogram. Compared with the systemic toxic effects of traditional chemotherapy, these side effects are more controllable and have less impact on quality of life.

Ribocilli's widespread acceptance can also be seen in real-world data. Riboxiclib still shows consistent and stable efficacy in breast cancer patients of different ages, hormonal status, and endocrine resistance. In addition, because reboxil can be taken orally, it greatly improves the convenience and compliance of patient treatment.

Reference materials:https://us.kisqali.com/